- Trafficking in Persons Report
- Special 301 Report (Intellectual Property Rights)
- International Narcotics Control Strategy Report
- Trade Policy Agenda and Annual Report
- Country Reports on Human Rights Practices
- Trade Estimate Report
- International Religious Freedom Report
- Country Reports on Terrorism
- Beyond the Border
Canada remains on the Watch List in 2016. The United States welcomed Canada’s amendment to its Copyright Act to extend protection for sound recordings to 70 years from the date of the recording. However, the United States continues to urge Canada to fully implement its commitments pursuant to the WIPO Internet Treaties and to continue to address the challenges of copyright piracy in the digital age. The United States remains deeply concerned that Canada does not provide customs officials with the ability to detain pirated and counterfeit goods that are moving in transit or are transshipped through Canada. As a result, the United States urges Canada to provide its customs officials with full
ex officio authority to improve its ability to address the serious problem of pirated and counterfeit goods entering our highly integrated supply chains.
With respect to pharmaceuticals, the United States continues to have serious concerns about
the availability of rights of appeal in Canada’s administrative process for reviewing regulatory approval of pharmaceutical products as well as about the breadth of the Minister of Health’s discretion in disclosing confidential business information. The United States also continues to have serious concerns about the lack of clarity and the impact of the heightened utility requirements for patents that have been imposed by Canadian courts. In these cases, courts have invalidated valuable patents held by U.S. pharmaceutical companies on utility grounds, by interpreting the “promise” of the patent and finding that insufficient information was provided in the application to substantiate that promise. These recent decisions, which have affected products that have been in the market and benefiting patients for years, have led to uncertainty for patent holders and applicants, including with respect to how to effectively meet this standard. This unpredictability also undermines incentives for investments in the pharmaceutical sector. The United States understands that the Supreme Court of Canada may have the opportunity to clarify this doctrine in the coming year. The United States urges Canada to engage meaningfully with affected stakeholders and the United States on patent utility issues. The United States also looks forward to working closely with Canada in the coming year to explore ways to address each country’s IPR priority issues.
Under the TPP Agreement, which sets strong and balanced standards on IPR protection and enforcement (See Trans-Pacific Partnership), Canada has committed to strengthen its IPR regime in many of these, as well as other, areas. The United States will work closely with Canada on TPP implementation.